10-Q quarterly report · filed Nov 5, 2026

VERACYTE, INC. (VCYT) Q3 2026 10-Q Quarterly Report

Short answer

VERACYTE, INC. (VCYT) filed its Q3 2026 10-Q quarterly report on Nov 5, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $152M (up 15.1% year over year) with net income of $32M.

Q3 2026 key financials · XBRL

Revenue
$152M
+15.1% YoY · +1.0% QoQ
Net income
$32M
+64.6% YoY · +23.6% QoQ
Operating margin
10.9%
Gross margin
70.6%
EPS (diluted)
$0.38
+58.3% YoY · +22.6% QoQ

Source: XBRL data from the VERACYTE, INC. (VCYT) Q3 2026 10-Q on SEC EDGAR. USD.

VERACYTE, INC. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Revenue $151.8M, up 15% YoY from $131.9M, driven by testing revenue up $18.7M
  • Net margin 20.8% vs 14.5% YoY, with operating margin 10.9% vs 17.4%
  • Testing revenue best performer: $146.4M, up 15%; biopharmaceutical revenue declined 106% from $8.7M
  • Cash and investments $370.5M, down $42.4M; operating cash flow $121.3M
  • Investing outflow $281.0M, including $153.2M acquisitions and $118.0M short-term investments
  • Outlook: continued cash generation, with payer constraints, reimbursement pressure, tariffs and geopolitical risks as headwinds

Risk Factors

  • No material changes from the 10-K risk factors
  • Carried-forward risks include diagnostic adoption, reimbursement, competition, regulatory compliance, and operating losses
  • Continued dependence on laboratory operations and uninterrupted testing capacity
  • Ongoing exposure to healthcare customer concentration and payment delays
  • Continued need for capital to fund operations and growth

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other VERACYTE, INC. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.